Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeru Imoto

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|August 28, 2019
A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database studyMakoto Kubo, Masaaki Kawai, Hiraku Kumamaru, et al.
Cancer Medicine|March 14, 2020
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamideKoji Matsumoto, Masato Takahashi, Kazuhiko Sato, et al.
Breast Cancer Research and Treatment|September 7, 2023
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancerMasahiro Takada, Shigeru Imoto, Takanori Ishida, et al.
Breast Cancer (Tokyo, Japan)|May 13, 2020
Annual report of the Japanese Breast Cancer Society registry for 2016Makoto Kubo, Hiraku Kumamaru, Urara Isozumi, et al.
Breast Cancer (Tokyo, Japan)|May 25, 2025
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational studyShigeru Imoto, Hiroyuki Yasojima, Takeshi Nagashima, et al.
NPJ Breast Cancer|October 24, 2025
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic surveyMasahiro Takada, Shigehira Saji, Takayuki Ueno, et al.
Breast Cancer (Tokyo, Japan)|June 22, 2022
Clinicopathological features of male patients with breast cancer based on a nationwide registry database in JapanAkihiko Shimomura, Masayuki Nagahashi, Hiraku Kumamaru, et al.
Breast Cancer (Tokyo, Japan)|July 26, 2020
Annual report of the Japanese Breast Cancer Registry for 2017Naoki Hayashi, Hiraku Kumamaru, Urara Isozumi, et al.
Breast Cancer Research and Treatment|October 23, 2022
Prognosis and effectiveness of chemotherapy for medullary breast carcinomaTomohiko Aihara, Hiraku Kumamaru, Makoto Ishitobi, et al.
Breast Cancer Research and Treatment|April 15, 2010
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 studyTomohiko Aihara, Yuichi Takatsuka, Shozo Ohsumi, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|August 28, 2019
A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database studyMakoto Kubo, Masaaki Kawai, Hiraku Kumamaru, et al.
Cancer Medicine|March 14, 2020
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamideKoji Matsumoto, Masato Takahashi, Kazuhiko Sato, et al.
Breast Cancer Research and Treatment|September 7, 2023
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancerMasahiro Takada, Shigeru Imoto, Takanori Ishida, et al.
Breast Cancer (Tokyo, Japan)|May 13, 2020
Annual report of the Japanese Breast Cancer Society registry for 2016Makoto Kubo, Hiraku Kumamaru, Urara Isozumi, et al.
Breast Cancer (Tokyo, Japan)|May 25, 2025
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational studyShigeru Imoto, Hiroyuki Yasojima, Takeshi Nagashima, et al.
NPJ Breast Cancer|October 24, 2025
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic surveyMasahiro Takada, Shigehira Saji, Takayuki Ueno, et al.
Breast Cancer (Tokyo, Japan)|June 22, 2022
Clinicopathological features of male patients with breast cancer based on a nationwide registry database in JapanAkihiko Shimomura, Masayuki Nagahashi, Hiraku Kumamaru, et al.
Breast Cancer (Tokyo, Japan)|July 26, 2020
Annual report of the Japanese Breast Cancer Registry for 2017Naoki Hayashi, Hiraku Kumamaru, Urara Isozumi, et al.
Breast Cancer Research and Treatment|October 23, 2022
Prognosis and effectiveness of chemotherapy for medullary breast carcinomaTomohiko Aihara, Hiraku Kumamaru, Makoto Ishitobi, et al.
Breast Cancer Research and Treatment|April 15, 2010
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 studyTomohiko Aihara, Yuichi Takatsuka, Shozo Ohsumi, et al.
Pageof 10